Literature DB >> 15245934

Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy.

Michael J Wehle1, David D Thiel, Steven P Petrou, Paul R Young, Igor Frank, Nolan Karsteadt.   

Abstract

OBJECTIVES: To describe small contrast-enhancing renal masses suggestive of cancer that were managed conservatively with watchful waiting and serial computed tomography scans. Advanced diagnostic imaging has led to the increased incidental detection of renal masses in patients whose multiple comorbid conditions preclude invasive management.
METHODS: A retrospective review was conducted of 29 consecutive patients with 29 incidentally detected asymptomatic renal masses less than 3.5 cm in diameter that were managed conservatively with watchful waiting (because of patient wishes or multiple comorbid conditions) and serial computed tomography scans.
RESULTS: The average patient age was 70 years (range 51 to 88), and the average duration of follow-up imaging was 32 months (range 10 to 89). The average number of follow-up computed tomography scans was 4.9 per patient (range 1 to 11). The average width of the renal masses at diagnosis was 1.83 cm (range 0.4 to 3.5), and the average change in size per year was 0.12 cm for all patients. Four patients underwent radical nephrectomy because of growth of the renal mass (n = 1) or patient wishes (n = 3). The histologic findings in 3 of these 4 patients were consistent with renal cell carcinoma. Two patients underwent radiofrequency ablation of the masses. At last follow-up, metastatic disease had not developed in any patient, and no patient had died of renal cell carcinoma. Two patients had died of other causes.
CONCLUSIONS: The results of our study showed that when comorbid conditions or patient wishes preclude invasive treatment, contrast-enhancing renal masses less than 3.5 cm wide that are suggestive of cancer can be safely managed with watchful waiting and serial computed tomography scans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15245934     DOI: 10.1016/j.urology.2004.02.026

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  30 in total

1.  Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.

Authors:  Pari V Pandharipande; Debra A Gervais; Rebecca I Hartman; Mukesh G Harisinghani; Adam S Feldman; Peter R Mueller; G Scott Gazelle
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

Review 2.  Image-guided radiofrequency ablation of renal cell carcinoma.

Authors:  Andreas Boss; Stephan Clasen; Markus Kuczyk; Fritz Schick; Philippe L Pereira
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

3.  Preoperative nomogram predicting 12-year probability of metastatic renal cancer.

Authors:  Ganesh V Raj; R Houston Thompson; Bradley C Leibovich; Michael L Blute; Paul Russo; Michael W Kattan
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

Review 4.  Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis.

Authors:  Marc C Smaldone; Alexander Kutikov; Brian L Egleston; Daniel J Canter; Rosalia Viterbo; David Y T Chen; Michael A Jewett; Richard E Greenberg; Robert G Uzzo
Journal:  Cancer       Date:  2011-07-15       Impact factor: 6.860

5.  Growth pattern of renal cell carcinoma (RCC) in patients with delayed surgical intervention.

Authors:  Xue-Song Li; Lin Yao; Kan Gong; Wei Yu; Qun He; Li-Qun Zhou; Zhi-Song He
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

6.  Optimal freeze cycle length for renal cryotherapy.

Authors:  Jennifer Lee Young; Elham Khanifar; Navneet Narula; Cervando Gerardo Ortiz-Vanderdys; Surendra Babu Kolla; Donald Lowell Pick; Petros George Sountoulides; Oskar Grau Kaufmann; Kathryn Elizabeth Osann; Victor Buu Huynh; Adam Geoffrey Kaplan; Lorena Aurora Andrade; Michael Ken Louie; Elspeth Marguerita McDougall; Ralph Victor Clayman
Journal:  J Urol       Date:  2011-05-20       Impact factor: 7.450

7.  Effectiveness and safety of computed tomography-guided radiofrequency ablation of renal cancer: a 14-year single institution experience in 203 patients.

Authors:  Jason D Iannuccilli; Damian E Dupuy; Michael D Beland; Jason T Machan; Dragan J Golijanin; William W Mayo-Smith
Journal:  Eur Radiol       Date:  2015-09-15       Impact factor: 5.315

Review 8.  Functional preservation in patients with renal cortical tumors: the rationale for partial nephrectomy.

Authors:  Paul Russo
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

9.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.

Authors:  Ariel A Williams; John P T Higgins; Hongjuan Zhao; Börje Ljunberg; James D Brooks
Journal:  BMC Clin Pathol       Date:  2009-11-18

10.  Watchful waiting in the treatment of the small renal mass.

Authors:  K Clint Cary; Chandru P Sundaram
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.